

Approved



South Sudan
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
USAID		8,134,503	2,010,000	10,144,503	289,002	10,433,505
DOD		1,188,200		1,188,200	245,000	1,433,200
HHS/CDC	200,000	9,461,599		9,661,599	0	9,661,599
Total	200,000	18,784,302	2,010,000	20,994,302	534,002	21,528,304

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency			On Hold Amount	Total
	DOD	HHS/CDC	USAID		
HBHC	0		607,618	0	607,618
HKID			669,694	0	669,694
HLAB		929,195		0	929,195
HMBL		133,629	50,000	0	183,629
HTXD		23,597	1,806,220	0	1,829,817
HTXS	462,311	4,020,132	3,077,740	0	7,560,183
HVCT	673,823	1,729,752	1,283,784	0	3,687,359
HVMS	0	1,128,652	667,480	0	1,796,132
HVOP	0		851,731	0	851,731
HVSI		767,663	188,000	0	955,663
HVTB	24,472	354,201	26,669	0	405,342
MTCT	27,594	289,860	344,129	0	661,583
OHSS		101,056	542,807	0	643,863
PDTX		183,862	28,631	0	212,493
	1,188,200	9,661,599	10,144,503	0	20,994,302

Approved





Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	607,618	0
HKID	625,418	0
HVTB	392,923	0
Total Technical Area Planned Funding:	1,625,959	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	805,000	0
HVSI	788,000	0
OHSS	577,087	0
Total Technical Area Planned Funding:	2,170,087	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	165,000	0
HVCT	3,562,357	0
HVOP	792,695	0
MTCT	592,469	0
Total Technical Area Planned Funding:	5,112,521	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
-------------	----------------------------	----------------

Approved



HTXD	1,747,184	0
HTXS	7,242,154	0
PDTX	141,848	0
Total Technical Area Planned Funding:	9,131,186	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	37,591
	Number of new ANC and L&D clients	41,680
	By: Known positives at entry	2,010
	By: Number of new positives identified	3,590
	Sum of Positives Status disaggregates	5,600
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNU's ONLY): <15	
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNUs ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	37,591
	New on ART	1,293
	Already on ART at beginning of current pregnancy	531
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,820
	Total estimated number of key population in the catchment area	6,936
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level	0



	HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	50
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,770
	By key population type: Males who	0



	inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	50
	By key population type: Transgender who are sex workers (Denominator: Total estimated	0



	number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	6,936
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report	



	period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	217,278
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female		



	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,884
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	110,249
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,999
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	96,137



Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	490
Test Result by Aggregated Age and Sex: Positive 15+ Male	7,667
Test Result by Aggregated Age and Sex: Positive <15 Female	542
Test Result by Aggregated Age and Sex: Positive 15+ Female	6,907
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point (Community): Index testing	1,122
Service Delivery Point (Community): Homebased testing	0
Service Delivery Point (Community): Mobile testing	42,275
Service Delivery Point (Community): Other	0
Service Delivery Point (Community) by Age: <15 index testing	
Service Delivery Point (Community) by Age: 15+ index testing	
Service Delivery Point (Community) by Age: <15 homebased testing	



	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	2,794
	Service Delivery Point (Facility): Outpatient	15,781
	Service Delivery Point (Facility): Pediatric	663
	Service Delivery Point (Facility): Malnutrition facilities	733
	Service Delivery Point (Facility): Other PITC	19,047
	Service Delivery Point (Facility): VCT	99,353
	Service Delivery Point (Facility): VMMC	0
	Service Delivery Point (Facility): PMTCT	33,866
	Service Delivery Point (Facility): TB Clinics	865
	Service Delivery Point (Facility): Index testing	780
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	



	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	



	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,662
	Total number of registered new and relapsed TB cases, during the reporting period.	2,013
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	50
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	821
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	47
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	764
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,000
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	300
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	600
	Sum of Age/Sex disaggregates	900



	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS	



	countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS	



	countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS	



	countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS	



	countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	1,500
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	1,600
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS	



	countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	237
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	257
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	



	ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	



	ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	116
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	100
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and	



	relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and	100



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	80
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	<p>Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	<p>0</p>
	<p>Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	<p>10</p>
	<p>Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	<p>0</p>
	<p>Aggregated Age/Sex: Female 15+ (Numerator: The number of</p>	<p>90</p>



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	22,508
	Screened for TB by Age/Sex: <15 Male	554
	Screened for TB by Age/Sex: 15+ Male	11,043
	Screened for TB by Age/Sex: <15 Female	665
	Screened for TB by Age/Sex: 15+ Female	10,247
	Screen Result: Screened Positive for TB	1,523
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,242
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,307
	[Sub-Disagg of Specimen Sent]	64



	Diagnostic Test: Xpert MTB/RIF assay	
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,308
	Screened for TB by Age/Sex: <15 Male	7
	Screened for TB by Age/Sex: 15+ Male	57
	Screened for TB by Age/Sex: <15 Female	2
	Screened for TB by Age/Sex: 15+ Female	14
	Screen Results: Screened Positive for TB	80
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	80
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	80
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0



PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	0
	By infants who received their first virologic HIV test between 2 and 12 months of age	0
	Sum of Infant Age disaggregates	0
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	0
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	0



PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	164
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,479
	Sum of Infant Age disaggregates	1,643
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	2
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	15



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	32,627
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	723
	Aggregated Age/Sex: 15+ Male	14,320
	Aggregated Age/Sex: <15 Female	783
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	16,621
	Sum of Aggregated Age/Sex <15	1,506
	Sum of Aggregated Age/Sex 15+	30,941
	Sum of Aggregated Age/Sex disaggregates	32,447
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
Age/Sex: 20-24 Female		
Age/Sex: 25-49 Female		
Age/Sex: 50+ Female		
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	5,293



	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	249
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	2,616
	Aggregated Age/Sex: <15 Female	184
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	2,244
	Sum of Aggregated Age/Sex <15	433
	Sum of Aggregated Age/Sex 15+	4,860
	Sum of Aggregated Age/Sex disaggregates	5,293
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	



	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	16,436
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	422
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	7,131
	Aggregated Grouping by Age/Sex: <1 Female	
Aggregated Grouping by Age/Sex: <15 Female	458	
Aggregated Grouping by Age/Sex:	7,770	



	15+ Female	
	Sum of Aggregated Age/Sex disaggregates	15,781
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,916
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1 Male		



	Aggregated Grouping by Age/Sex: <15 Male	131
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	1,440
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	98
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,247
	Sum of Aggregated Age/Sex disaggregates	2,916
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	6,068
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records	6,699



	in the past 12 months.	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication:	



	25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	
	Numerator: Indication: Targeted	6,068
	Numerator: Preg/BF by Indication:	



	Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	6,699
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by	



	Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex	



	by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	94
	Numerator Aggregated Age/Sex: 15+ Male	2,307
	Numerator Aggregated Age/Sex: <15 Female	170
	Numerator Aggregated Age/Sex: 15+ Female	3,431
	Denominator Aggregated Age/Sex: <15 Male	125
	Denominator Aggregated Age/Sex: 15+ Male	2,463
	Denominator Aggregated Age/Sex: <15 Female	210
	Denominator Aggregated Age/Sex: 15+ Female	3,871
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who	6,113



	are still alive and on treatment at 12 months after initiating ART	
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,473
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior	



	<p>to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	



	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the</p>	



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	



	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	152
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,409
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	171
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,381
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	230
	Aggregated Age/Sex: 15+ Male	4,727



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	280
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,236
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	11
	CD4: Number of laboratories that participate in this PT program	14
	CD4: Number of laboratories that perform this testing	14



	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this testing	1
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	38
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	48
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	48
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that participate in this PT program	1
	HIV viral load: Number of laboratories that perform this testing	1
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (AFB microscopy):	0



	Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	366,844
	Number of HIV Test Kits purchased	283,988
	Number of HIV CD4 Reagents purchased	64,788
	Number of Condoms purchased	0
	Number of HIV Viral Load Reagents purchased	7,752

Approved



	Number of HIV ARVs purchased	10,316
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	238,500
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	647,880
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	155,040
	Condoms: Dollars planned (COP)/ spent (Actual)	0
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	1,038,154



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
14418	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17700	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,150,000
17701	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,917,520
17708	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,309,639



17713	FHI 360	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	2,274,062
17714	JHPIEGO	University	U.S. Agency for International Development	GHP-State	2,019,287
17805	Research Triangle International	Private Contractor	U.S. Department of Defense	GHP-State	1,188,200
17832	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,610,620
18133	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	625,418
18236	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	4,145,007
18397	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 14418	Mechanism Name: Intrahealth SI-OHSS (ENDED March 31/2017)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14418		
Mechanism Name:	Intrahealth SI-OHSS (ENDED March 31/2017)		
Prime Partner Name:	IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0
------------------------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17700	Mechanism Name: AMREF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,150,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,150,000	
Funding Source	Funding Amount
GHP-State	1,150,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17700			
Mechanism Name: AMREF			
Prime Partner Name: African Medical and Research Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	805,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	115,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	230,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	164
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	1,479
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,643
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	2
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	15
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	6,068
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,699
TX_PVLS_TA	Numerator: Indication: Targeted	6,068
TX_PVLS_TA	Denominator: Indication: Targeted	6,699
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	94



TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	2,307
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	170
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	3,431
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	125
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	2,463
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	210
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	3,871
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	11
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	14
LAB_PT_TA	CD4: Number of laboratories that perform this testing	14
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	38
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	48
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	48
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of	0



	laboratories that achieve acceptable successful passing criteria in this PT program	
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	0
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0

Implementing Mechanism Details

Mechanism ID: 17701	Mechanism Name: International Center for AIDS Care and Treatment Programs, Columbia University
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,917,520	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,917,520	



Funding Source	Funding Amount
GHP-State	2,917,520

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17701		
Mechanism Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	228,697	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	473,506	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	60,355	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,075,125	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	79,837	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,462
PMTCT_ART_DSD	New on ART	82
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	83
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,462
PMTCT_STAT_DSD	Number of new ANC and L&D clients	4,958
PMTCT_STAT_DSD	By: Known positives at entry	58
PMTCT_STAT_DSD	By: Number of new positives identified	58
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	116
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	23,840
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,512
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,208
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,807
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,313
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,319
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	20,521
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	23,840
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	122
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	658
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	146
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	985



	Female	
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	11,920
HTC_TST_DSD	Service Delivery Point (Facility): VCT	11,920
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	416
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	554
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	17
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	149
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	24
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	226
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	42
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	42
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	4



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	7,306
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	365
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,594
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	457
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	3,890
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	731
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	548
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	552
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,600
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	355
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,939
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	398
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,908
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	753
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	9,847
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	10,600
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,618
TX_CURR_TA	Aggregated Age/Sex: <15 Male	28
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	632
TX_CURR_TA	Aggregated Age/Sex: <15 Female	37
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	921



TX_CURR_TA	Sum of Aggregated Age/Sex <15	65
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,553
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,618
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,882
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	200
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,596
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	240
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,394
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,430
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,064
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	19
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	441
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	23
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	581
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,064
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,231
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,430
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	131
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,189
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	143
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	1,768



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	200
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,596
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	240
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,394

Implementing Mechanism Details

Mechanism ID: 17708	Mechanism Name: IHI - prevention, care and treatment
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,309,639	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,309,639	
Funding Source	Funding Amount



GHP-State	1,309,639
-----------	-----------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17708			
Mechanism Name: IHI - prevention, care and treatment			
Prime Partner Name: IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	47,363	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	31,899	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	469,939	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	129,771	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	611,170	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	19,497	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,570
PMTCT_ART_DSD	New on ART	493
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,570
PMTCT_STAT_DSD	Number of new ANC and L&D clients	11,050
PMTCT_STAT_DSD	By: Known positives at entry	98
PMTCT_STAT_DSD	By: Number of new positives identified	268
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	366
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	28,803
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	377
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,155
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	319
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	19,952
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	696
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	28,107
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	28,803
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	85
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	703
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	84

	Female	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	861
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,890
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	2,859
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	663
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	733
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2,240
HTC_TST_DSD	Service Delivery Point (Facility): VCT	9,206
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	9,570
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	862
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	780
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	297
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	297
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	26
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	136
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	20
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	115
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	30
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	30

TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,156
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	70
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,637
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	58
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	1,391
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	123
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	123
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	223
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,946



TX_CURR_DSD	Aggregated Age/Sex: <15 Male	116
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,782
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	89
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,959
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	205
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,741
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,946
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,956
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	78
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	569
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	61
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,045
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,753
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	628
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	897
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	286
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	293
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	30



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	402
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	40
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	425

Implementing Mechanism Details

Mechanism ID: 17713	Mechanism Name: Linkages
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,274,062	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,274,062	
Funding Source	Funding Amount
GHP-State	264,062
GHP-USAID	2,010,000



Cross-Cutting Budget Attribution(s)

Condom programming	300,000
Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Key Populations: FSW	2,065,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG

Budget Code Information

Mechanism ID:	17713
----------------------	--------------



Mechanism Name: Linkages			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	535,618	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	5,680	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	10,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	246,435	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	792,695	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	663,634	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,820



KP_PREV_DSD	Total estimated number of key population in the catchment area	6,936
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	50
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,770
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence	0

	and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	50
KP_PREV_DSD	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	6,936
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,338
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	0



	ONLY: <15 Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	45
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,293
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	4,338
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,338
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	10
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	771
HTC_TST_DSD	Service Delivery Point (Community): Index testing	0
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	4,338
HTC_TST_DSD	Service Delivery Point (Community): Other	0
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	0
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0

TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	758
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	756
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	26
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	26
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	26
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	0
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	0
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	0
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	0
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	0
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	0
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,084
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,079
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,084
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,084



TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0
TX_CURR_TA	Aggregated Age/Sex: <15 Male	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	0
TX_CURR_TA	Aggregated Age/Sex: <15 Female	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	0
TX_CURR_TA	Sum of Aggregated Age/Sex <15	0
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	0
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	735
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	5
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	730
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	735
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	0
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	0

Implementing Mechanism Details

Mechanism ID: 17714	Mechanism Name: SPPHC
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,019,287	
---	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,019,287	
Funding Source	Funding Amount
GHP-State	2,019,287

Cross-Cutting Budget Attribution(s)

Human Resources for Health	300,000
----------------------------	---------

Budget Code Information

Mechanism ID: 17714			
Mechanism Name: SPPHC			
Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	72,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	20,989	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	168,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	127,899	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	754,573	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	182,923	0
Treatment	HTXS	679,030	0
Treatment	PDTX	13,873	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,454
PMTCT_ART_DSD	New on ART	497
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	152
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,454
PMTCT_STAT_DSD	Number of new ANC and L&D clients	17,062
PMTCT_STAT_DSD	By: Known positives at entry	160
PMTCT_STAT_DSD	By: Number of new positives identified	716
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	876
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	51,953
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,333
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,275
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,328



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	32,008
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,661
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	49,283
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	51,944
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	48
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,168
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	48
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,404
HTC_TST_DSD	Service Delivery Point (Community): Index testing	1,122
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	8,544
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	26,834
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	15,454
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	769
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	962
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	383
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	0



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	386
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	78
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	98
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	39
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	39
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,409
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	17
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,200
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	17
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	1,176
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	563

TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	545
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	506
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	64
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_DSD	Sum of Infant Age disaggregates	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,199
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	93
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,646
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	90
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,190
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	183
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,836
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,019
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,379
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	88
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,387
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	85
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,819
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,379



Implementing Mechanism Details

Mechanism ID: 17805	Mechanism Name: RTI Care and Treatment
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,188,200	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,188,200	
Funding Source	Funding Amount
GHP-State	1,188,200

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17805			
Mechanism Name: RTI Care and Treatment			
Prime Partner Name: Research Triangle International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	24,472	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	673,823	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	27,594	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	462,311	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,040
PMTCT_ART_DSD	New on ART	20
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	62
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,040
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,545
PMTCT_STAT_DSD	By: Known positives at entry	62
PMTCT_STAT_DSD	By: Number of new positives identified	20
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	82
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	55,848
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	98
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	49,674
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	147
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,929
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	245
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	55,603
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	55,848



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	24
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,993
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	37
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	558
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	37,937
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	4,198
HTC_TST_DSD	Service Delivery Point (Facility): VCT	11,673
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	2,040
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	100
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	100
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	63
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	27
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	80
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	80



TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	50
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	5,108
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	4,267
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	841
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	80
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,675
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,741
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	934
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,675
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	5,675
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,146
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,729
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	417



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,146
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,254
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,146
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,934
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	320
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,729
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	417

Implementing Mechanism Details

Mechanism ID: 17832	Mechanism Name: CMMB - Prevention, Care and Treatment
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,610,620	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 1,610,620	
Funding Source	Funding Amount
GHP-State	1,610,620

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17832			
Mechanism Name: CMMB - Prevention, Care and Treatment			
Prime Partner Name: Catholic Medical Mission Board			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	65,722	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	31,899	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	705,581	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	74,896	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	703,881	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	28,641	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,025
PMTCT_ART_DSD	New on ART	201
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	234
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,025
PMTCT_STAT_DSD	Number of new ANC and L&D clients	4,025
PMTCT_STAT_DSD	By: Known positives at entry	1,550
PMTCT_STAT_DSD	By: Number of new positives identified	2,475
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,025
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	34,413
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	936
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,246
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,217
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,014
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,153
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	32,260
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	34,413
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	211
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	834

	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	227
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,002
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	4,345
HTC_TST_DSD	Service Delivery Point (Facility): VCT	24,531
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	5,537
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,771
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	102



TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,343
TB_SCREENDX_DSD	Screened for TB by Age/Sex: <15 Female	133
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	2,193
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,123
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	159
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,207
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	206
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,551
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	365
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,758
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,123
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,338
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	56
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	845
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	72
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,365
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,338

Implementing Mechanism Details

Mechanism ID: 18133	Mechanism Name: 4 Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 625,418	
Applied Pipeline Amount: 289,002	
Total All Funding Sources and Applied Pipeline Amount: 914,420	
Funding Source	Funding Amount
GHP-State	625,418



Cross-Cutting Budget Attribution(s)

Economic Strengthening	100,000
Education	100,000

Budget Code Information

Mechanism ID: 18133			
Mechanism Name: 4 Children			
Prime Partner Name: Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	625,418	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,000
OVC_SERV_DSD	Age/Sex: 18+ Male	300
OVC_SERV_DSD	Age/Sex: 18+ Female	600
OVC_SERV_DSD	Sum of Age/Sex disaggregates	900
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,500
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,600

Implementing Mechanism Details

Mechanism ID: 18236	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract



Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 4,145,007	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,145,007	
Funding Source	Funding Amount
GHP-State	4,145,007

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18236		
Mechanism Name:	Global Health Supply Chain Program		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	375,390	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	238,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	116,930	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	1,747,184	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,617,003	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	366,844
INVS_COMD	Number of HIV Test Kits purchased	283,988
INVS_COMD	Number of HIV CD4 Reagents purchased	64,788
INVS_COMD	Number of Condoms purchased	0
INVS_COMD	Number of HIV Viral Load Reagents purchased	7,752
INVS_COMD	Number of HIV ARVs purchased	10,316
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	238,500
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	647,880
INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	155,040
INVS_COMD	Condoms: Dollars planned (COP)/ spent (Actual)	0
INVS_COMD	HIV ARVs: Dollars planned (COP)/ spent (Actual)	1,038,154

Implementing Mechanism Details

Mechanism ID: 18397	TBD: Yes
REDACTED	

Agency Information - Costs of Doing Business U.S. Agency for International Development



Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		10,597		0	10,597	10,597
ICASS		184,000		0	184,000	184,000
Institutional Contractors		172,206		0	172,206	172,206
Management Meetings/Professional Development		30,000		0	30,000	30,000
Non-ICASS Administrative Costs		26,617		0	26,617	26,617
Staff Program Travel		30,205		0	30,205	30,205
USG Staff Salaries and Benefits - Internationally Recruited		199,863		0	199,863	199,863
USG Staff Salaries and Benefits - Locally Recruited		427,241		0	427,241	427,241
Total	0	1,080,729	0	0	1,080,729	1,080,729



U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		0		100,000	0	100,000
Management Meetings/Professional Development		0		25,000	0	25,000
Staff Program Travel		0		50,000	0	50,000
USG Staff Salaries and Benefits - Locally Recruited		0		70,000	0	70,000
Total	0	0	0	245,000	0	245,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
-------------------------------	-----	-----------	-----------	------------------	-------	---

Approved



Capital Security Cost Sharing		108,789		0	108,789	108,789
Computers/IT Services		30,000		0	30,000	30,000
ICASS		491,211		0	491,211	491,211
Management Meetings/Professional Development		121,150		0	121,150	121,150
Non-ICASS Administrative Costs		36,847		0	36,847	36,847
Staff Program Travel		131,685		0	131,685	131,685
USG Staff Salaries and Benefits - Internationally Recruited	200,000			0	200,000	200,000
USG Staff Salaries and Benefits - Locally Recruited		754,138		0	754,138	754,138
Total	200,000	1,673,820	0	0	1,873,820	1,873,820